Ironwood Pharmaceuticals price to free cash flow IRWD

Market value divided by free cash flow over the last twelve months, since 2020.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 6.2×; Jul 2026
7-year median: 6.2×
7-year range: 1.1× to 462×
Peer median: 7.5×

Ironwood Pharmaceuticals' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Jul 2026, at 6.2×.

On the days it had one over the last 7 years, its median was 6.2×, from 1.1× in May 2025 to 462× in Apr 2020.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	6.2×	3.9×	12.6×
2025	7.7×	1.1×	10.4×
2024	5.8×	4.3×	12.9×
2023	7.9×	4.9×	7.9×
2022	7.3×	6.7×	7.3×
2021	n/m a value too high to mean anything
2020	16.3×	16.3×	462×

Against its peers

Companies in Drug Manufacturers - General nearest Ironwood Pharmaceuticals' size, closest first, today.

Company	Price to free cash flow
IRWDIronwood Pharmaceuticals	n/m
PBYIPuma Biotechnology	13.8×
ZVRAZevra Therapeutics	17.9×
CRMDCorMedix	2.4×
ARVNArvinas	n/m
COLLCollegium Pharmaceutical	2.3×
ABUSArbutus Biopharma	n/m
AMPHAmphastar Pharmaceuticals	7.0×
OMEROmeros	n/m
PCRXPacira BioSciences	8.1×
ANABAnaptysbio	n/m
Peer median	7.5×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Ironwood Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.